Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 249.91 on Tuesday. Puma Biotechnology has a 1-year low of $33.70 and a 1-year high of $263.34. The stock’s 50-day moving average is $166.2 and its 200-day moving average is $108.3. The company’s market cap is $7.527 billion.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.93 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a buy rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an outperform rating on the stock.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.